北京天坛生物制品股份有限公司2025年半年度业绩快报公告

Financial Performance - In the first half of 2025, the company's operating revenue increased by 9.47% year-on-year due to sales volume growth [1] - The net profit attributable to shareholders of the listed company decreased by 12.88% year-on-year, influenced by a decline in product sales prices and reduced interest income due to changes in credit policies [1] Operational Highlights - The company operated 85 plasma collection companies, achieving a plasma collection of 1,361 tons, which represents a year-on-year growth of 0.7% [2]